Skip to main content

AQNEURSA

Generic: levacetylleucine

Data may be stale·Apr 23, 2026
Manufacturer
IntraBio
NDC
83853-101
RxCUI
2693617
Route
ORAL
ICD-10 indication
G89.22

Affordability Check

How much will you actually pay for AQNEURSA?

In 30 seconds, see every legitimate way to afford AQNEURSA — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About AQNEURSA

What is this medication?

Aqneursa is a prescription medicine used to treat the neurological symptoms of Niemann-Pick disease type C, which is a rare and progressive genetic disorder. This condition interferes with the body's ability to move cholesterol and other fats within cells, leading to a buildup that primarily affects the brain and nervous system. The medication is specifically indicated for use in both adults and pediatric patients who weigh at least 15 kilograms to help manage the complex neurological manifestations of the disease.

The active ingredient in Aqneursa is levacetylleucine, a modified version of a natural amino acid. While the specific way it works is not entirely clear, it is intended to help improve or stabilize various neurological functions such as balance, coordination, and speech. By targeting these symptoms, the medication aims to enhance the daily functional abilities of individuals living with this serious and life-limiting condition.

Copay & patient assistance

  • Patient Copay Amount: Not Publicly Available
  • Maximum Annual Benefit Limit: Not Publicly Available
  • Core Eligibility Restrictions: Not Publicly Available
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How AQNEURSA appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

4%

228 of 5,499 plans

Most common tier

Tier 5

On 77% of covering formularies

Prior authorization required

94%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)6
19%
Tier 2 (generic)1
3%
Tier 5 (specialty)24
77%

Step therapy: 0% of formularies

Quantity limits: 77% of formularies

Coverage breadth: 31 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

Yes——

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.